Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 8%
Hold 67%
Sell 25%
Strong Sell 0%

Bulls say

Moderna is a rapidly growing biotech company with a promising pipeline of mRNA-based therapies in various therapeutic areas. Their pioneering mRNA technology, validated by the success of their COVID-19 vaccine, positions the company for long-term success. With a solid balance sheet, a diverse and innovative pipeline, and successful clinical trial data, Moderna is well-positioned for future growth and potential partnerships.

Bears say

Moderna is at a high-risk for stock price volatility and future revenue instability due to the uncertainty of the success of their varied and wide-ranging pipeline, recent discontinuations of certain programs, and the possibility of future program failures. Additionally, the current market cap of $24.64 billion is significantly higher than the projected YE:26E cash of $3.71 billion, which leads to concerns about financial stability and the use of the Ares credit facility. Further, the potential setbacks in trials for the COVID-19 vaccine, as well as the unproven efficacy of cancer vaccines, are cause for caution and leads to a negative outlook for Moderna.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 8% recommend Buy, 67% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.